Shanghai, March 30, 2023 – To promote a long-term mutually beneficial strategic partnership, BioDuro-Sundia recently signed a strategic cooperation agreement with Suzhou Kanwhish Biotechnology Co., Ltd.
BioDuro-Sundia is the industry-leading integrated CRDMO for drug discovery, development and manufacturing. BioDuro-Sundia Drug Discovery department provides end-to-end services ranging from hit identification to lead optimization and candidate compound selection. At the same time, it has built a series of cutting-edge platforms such as PROTAC, Fragment-based drug discovery (FBDD) capability, DNA-encoded library (DEL), Nanobody, NASH model, etc. As an expert in drug discovery, the company has successfully delivered thousands of projects to date and has advanced multiple candidate compounds into clinic globally.
In order to better develop the new drug R&D market in China and internationally, and to further expand and specialize the CRO platform and business, BioDuro-Sundia and Kanwhish have established a strategic partnership. The partnership integrates complimentary capabilities, positioning both parties and respective clients for joint success. Together, BioDuro-Sundia and Kanwhish have built a leading new drugs R&D platform in China, which integrates BioDuro-Sundia's powerful small molecule DMPK analysis capabilities with Kanwhish's premier large and small molecule bioanalysis platform.
The strategic cooperation agreement is not only conducive to the establishment of sustained and stable cooperative relations between the two enterprises, but also seeks complementary advantages and mutual benefit. It is conducive to the long-term development of both companies. We firmly believe the shared professionalism of BioDuro-Sundia and Kanwhish will inspire great possibility for cooperation and development.
BioDuro-Sundia, an Advent International portfolio company, is a trusted, leading contract research development, and manufacturing organization (CRDMO) for over 27 years. We provide our biotech and pharmaceutical partners with fully integrated services to support their efforts from target identification through to commercial drug product manufacturing. The company is based in the US and China with more than 3,000 employees and 10 global sites across 7 cities.
Core expertise includes small and large molecule discovery, development and scale up, support for IND submission, and unique technology platforms such as bioavailability enhancement of insoluble compounds. The one-stop-shop operation helps biotech and pharma partners across the globe to significantly accelerate discovery and de-risk development to create higher value outcomes. We adhere to one global highest standard of compliance and business operation code. Our science-driven, customer-oriented, people-focused culture enables us to provide top-tier integrated, fast, and flexible tailored services to our customers, to meet their unique needs and accelerate development timelines. For more information, please visit www.bioduro-sundia.com.
Suzhou Kanwhish Biotechnology Co., Ltd. is committed to providing comprehensive and one-stop bioanalytical services, covering preclinical/clinical pharmacokinetic, pharmacodynamic, immunogenicity and biomarker sample analysis, central lab sample management, as well as the R&D and sale of high-end analytical instruments, consumables, reagents. Kanwhish built 3,000 m2 GLP laboratories in LifeBay, Wuzhong District, the lab area includes a Class 100,000 clean laboratory designed for bioanalysis of CGT products, and a BSL-2-level laboratory equipped with Watson LIMS and professional analytical instruments. From research only assays to studies that require GCLP- or GLP-compliant assays, Kanwhish has the technology platforms, the expertise and the quality system needed to develop customized solutions for our customers.
Kanwhish adheres to the mission of "To promote bioanalysis industry development and accelerate new drug development". Our full-process bioanalysis service platform not only provides high-quality bioanalytical services, which is compliant with regulations of global regulatory agencies, to accelerate and improve success rate of regulatory submissions. But also provides high-end analytical instruments, and supporting consumables and reagents which helps to build a low-cost industrial chain ecology and further build a highly automated and highly sensitive analysis capabilities for bioanalytical industry.